Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing
May 04 2023 - 4:30PM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, is
pleased to announce the appointment of Michael Wysocki to the
position of Senior Vice President, Sales and Marketing.
Wysocki joins the Company with nearly two
decades of experience at General Electric and GE Healthcare. During
his GE career, he held roles of increasing responsibility in their
imaging, molecular imaging and computed tomography (CT) businesses
before becoming the General Manager, U.S. Molecular Imaging,
Pharmaceutical Diagnostics. In this role, he was responsible for
all commercial activities and long-term strategic planning within
the Neurology and Nuclear business segments.
“We are excited to welcome Mike to Rapid Micro,
where he will join our executive leadership team,” said President
and CEO Robert Spignesi. “He is a recognized commercial leader and
brings a proven track record of implementing successful sales
strategies that have driven significant revenue growth. This
experience will be invaluable as we focus on accelerating Growth
Direct® system placements.”
Most recently, Wysocki was Chief Commercial and
Strategy Officer at SOC Telemed, Inc., a tech-enabled clinical
services company, where he led a cross functional team of
commercial leaders and was responsible for developing a
go-to-market strategy to achieve its growth objectives. He holds a
BS in Biology from Boston College.
“I’m very excited to join Rapid Micro and
embrace the Company’s vision for the Growth Direct platform to
support manufacturers of life-saving therapies through microbial
quality control automation,” said Wysocki. “I am eager to partner
with Rapid Micro’s impressive customer base, in addition to working
alongside its talented sales, marketing and support teams, to help
achieve even greater levels of success.”
About Rapid Micro
Biosystems
Rapid Micro Biosystems is an innovative life
sciences technology company providing mission critical automation
solutions to facilitate the efficient manufacturing and fast, safe
release of healthcare products such as biologics, vaccines, cell
and gene therapies, and sterile injectables. The Company’s flagship
Growth Direct System automates and modernizes the antiquated,
manual microbial quality control (“MQC”) testing workflows used in
the largest and most complex pharmaceutical manufacturing
operations across the globe. The Growth Direct System brings the
quality control lab to the manufacturing floor, unlocking the power
of MQC automation to deliver the faster results, greater accuracy,
increased operational efficiency, better compliance with data
integrity regulations, and quicker decision making that customers
rely on to ensure safe and consistent supply of important
healthcare products. The Company is headquartered and has U.S.
manufacturing in Lowell, Massachusetts, with global locations in
Lexington, Massachusetts, Switzerland, Germany, and the
Netherlands. For more information, please visit
www.rapidmicrobio.com or follow the company on Twitter at
@rapidmicrobio or on LinkedIn.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jul 2023 to Jul 2024